Table 1.
Characteristics of patients who underwent a kidney transplant at Centre Hospitalier de l’Université de Montréal between 2008 and 2017 for whom a graft biopsy was available pretransplantation and post-transplantation
| Characteristics | Delayed Graft Function, n=61 | Immediate Graft Function, n=130 |
|---|---|---|
| Recipient characteristics | ||
| Age, yr, mean (SD) | 48 (12) | 49 (13) |
| Sex, women, n (%) | 17 (28) | 51 (39) |
| Smoker or ex-smoker, n (%) | 34 (56) | 63 (48) |
| Weight, kg, mean (SD) | 77 (18) | 71 (15) |
| Height, m, mean (SD) | 1.70 (0.10) | 1.69 (0.09) |
| Race, n (%) | ||
| White | 46 (75) | 96 (74) |
| Black | 6 (10) | 10 (8) |
| Cause of CKD, n (%) | ||
| Glomerular diseases | 22 (36) | 51 (39) |
| Diabetes | 9 (15) | 13 (10) |
| Hypertension/vascular | 5 (8) | 6 (4) |
| Polycystic kidney disease | 10 (16) | 30 (23) |
| Autoimmune disease | 3 (5) | 7 (5) |
| Urologic | 9 (15) | 14 (11) |
| Unknown | 11 (15) | 15 (10) |
| Diabetes, n (%) | 14 (23) | 17 (13) |
| First transplantation, n (%) | 62 (83) | 131 (90) |
| Preemptive transplantation, n (%) | 5 (8) | 20 (15) |
| Median time on dialysis before transplantation, mo (IQR) | 45 (18–44) | 31 (9–54) |
| Pretransplant panel-reactive antibodies >0%, n (%) | 10 (16) | 17 (13) |
| Statin use at transplantation, n (%) | 24 (39) | 69 (53) |
| ACE inhibitor use at transplantation, n (%) | 16 (26) | 67 (52) |
| Donor characteristics | ||
| Donor type, n (%) | ||
| Living donor | 4 (7) | 56 (43) |
| Neurologic determination of death | 43 (70) | 69 (53) |
| Donation after cardiac death | 14 (23) | 5 (4) |
| Age, yr, mean (SD) | 47 (15) | 47 (13) |
| Sex, women, n (%) | 34 (56) | 65 (50) |
| Hypertension, n (%) | 14 (23) | 16 (12) |
| Diabetes, n (%) | 5 (8) | 4 (3) |
| Smoker or ex-smoker, n (%) | 29 (48) | 46 (35) |
| Mean donor creatinine, mg/dl (SD) | 0.77 (0.38) | 0.76 (0.25) |
| Median number of HLA mismatches (IQR) | 4 (3–4) | 4 (3–5) |
| Use of hypothermic perfusion machine, n (%) | 22 (36) | 71 (55) |
| Preimplantation biopsy findings | ||
| Median % global glomerulosclerosis (IQR) | 4 (0–7) | 3 (1–6) |
| Interstitial fibrosis (ci) score, n (%) | ||
| 0 | 36 (59) | 95 (73) |
| 1 | 22 (36) | 31 (24) |
| 2 | 3 (5) | 4 (3) |
| 3 | 0 (0) | 0 (0) |
| Vascular fibrous intimal thickening (cv) score, n (%) | ||
| 0 | 36 (59) | 62 (48) |
| 1 | 12 (20) | 29 (22) |
| 2 | 11 (18) | 35 (27) |
| 3 | 2 (3) | 4 (3) |
| Peritransplantation events | ||
| Cold ischemic time, h, mean (SD) | 10 (5) | 8 (5) |
| Warm ischemic time, min, mean (SD) | 39 (11) | 38 (10) |
| Induction, n (%) thymoglobulin | 28 (47) | 27 (21) |
| Post-transplant biopsy | ||
| Median time to biopsy, d (IQR) | 106 (21–117) | 117 (104–129) |
| Surveillance biopsy, n (%) | 54 (89) | 121 (93) |
| Rejection before/on surveillance biopsy, n (%) | 18 (30) | 23 (18) |
| T cell mediated, borderline | 13 (72) | 13 (56) |
| T cell mediated, Banff grade 1A | 3 (17) | 7 (30) |
| T cell mediated, Banff grade 2A | 2 (11) | 0 (0) |
| Antibody mediated | 0 (0) | 2 (9) |
| Chronic T cell–mediated rejection | 0 (0) | 1 (4) |
IQR, interquartile range; ACE, angiotensin-converting enzyme; ci, Banff score for interstitial fibrosis; cv, Banff score for vascular fibrous intimal thickening.